Yuki Nakamura_No.5
Selected journal : Nature
Hepatocytes promote liver metastasis of pancreatic cancer by providing serine
What is the main question of the paper?
How do pancreatic cancer cells—which cannot synthesize serine on their own—adapt to and proliferate in the liver metastasis microenvironment?
How did the anthor address the question?
■Step1
1. Discovering that hepatocytes supply the serine necessary for hepatic metastasis of pancreatic cancer Authors first investigated how pancreatic cancer cells—which have low expression of the serine synthase PHGDH and are dependent on exogenous serine—are able to proliferate in the liver. Using a mouse model of pancreatic cancer liver metastasis, co-culture of cancer cells and hepatocytes, and serine metabolism analysis, they demonstrated that serine synthesis is enhanced in hepatocytes surrounding the metastatic lesions and that this serine supports the proliferation of pancreatic cancer cells. This revealed that hepatocytes function as metabolic partners that supply nutrients to metastatic cancer cells.
■Step2
2. Elucidation of molecular mechanism by which cancer cells induce serine synthesis in hepatocytes Next, they investigated how pancreatic cancer cells promote serine synthesis in hepatocytes. Through gene expression analysis, cell culture assays, signal transduction analysis, and manipulation of gene expression, they demonstrated that CXCL5 secreted by cancer cells acts on CXCR2 in hepatocytes to activate the PI3K–AKT pathway. As a result, they revealed that the transcription factor FOXO3A is sequestered into the cytoplasm, and the repression of PHGDH transcription is lifted, thereby enhancing serine synthesis in hepatocytes. In other words, they identified a mechanism by which cancer cells reprogram the metabolism of normal hepatocytes via secreted factors.
■Step3
3. Demonstrating that inhibiting serine supply from hepatocytes can suppress liver metastases Finally, they investigated whether this metabolic crosstalk is actually necessary for the progression of liver metastases. They generated mice with hepatocyte-specific Phgdh and Cxcr2 gene deletions, performed pharmacological inhibition of the signaling pathways, implemented a serine-restricted diet, and conducted tumor burden and survival analyses in a mouse model of liver metastasis. The results showed that inhibiting serine synthesis in hepatocytes or the CXCL5–CXCR2 signaling pathway suppressed liver metastasis of pancreatic cancer and prolonged survival. Furthermore, the effect was enhanced when combined with a serine-restricted diet, demonstrating that serine supply by hepatocytes could be a potential therapeutic target.
What is the “strength” of the paper?
The strength of this study lies in its causal demonstration—from the molecular to the organismal level—of a novel metastasis mechanism in which cancer cells reprogram the metabolism of normal liver cells to compensate for their own metabolic deficiencies.
Comment
A key highlight of the paper is the strict spatial localization of metabolic reprogramming. Increased serine synthesis does not occur throughout the liver parenchyma, but is restricted to hepatocytes immediately adjacent to tumor cells. Notably, when hepatocyte Phgdh is deleted, surviving micro-clusters only establish near hepatocytes retaining residual PHGDH expression. This strict spatial overlap offers definitive in situ proof of hepatocyte-derived metabolic support in tumor colonization.
Comment by Xiaoran Ma
